Patent & Trade Mark


Japan joined the ‘Patent Cooperation Treaty’ (PCT) in October 1978 and in 2015, the Japan Australia Economic Partnership Agreement (JAEPA) entered into force to pave the way for further growth in two-way investment and trade between the two complementary economies.

For further information on filing in Japan, please contact Patrick McManamny.

Economic Overview

Japan’s economy is the third largest in the world, having only been overtaken by China in 2010. It is also one of the world’s largest consumer markets thanks to a well-educated, hardworking workforce with large disposable income.

Manufacturing has been a key component to Japan’s economic growth between 1960 and 1980, and it is now a global leader in production of:

  • appliances
  • electronics
  • automobiles
  • ships
  • precision and optical equipment
  • machine tools
  • chemicals, and
  • machinery.

In April 2016, export of these goods to the United States, China, and the Republic of Korea contributed to 17 per cent of the Japanese GDP.

The Japanese economy is currently facing challenges due to their energy policy; Australia is well placed to benefit from the government’s encouragement for Japanese firms to invest in natural resources overseas.

Bilateral Relations

In 2007, a comprehensive partnership was established between Japan and Australia through the 2007 Joint Declaration on Security Cooperation. This was followed in 2015 by the aforementioned Japan-Australia Economic Partnership Agreement.

Patrick McManamny

Dr Patrick McManamny regularly counsels clients in relation to filing and management of international patent portfolios, freedom-to-operate issues, patentability and due diligence. His clients include large multi-national clients, start-up companies and research institutes.  Patrick has also served a brief period as in-house counsel, which provided valuable insight into the responsibilities of this role.

Patrick manages the patent portfolios of a number of Japanese companies and travels there regularly to visit both clients and his extensive network of associate firms. He also keeps a finger on the pulse in Japan's thriving biotechnology industry.

16 Sep 2017
At FB Rice, we recognise that diversity is a strength and that we are a better firm for having people with different ethnicity, sex, gender identity, sexual orientation and backgrounds.

06 Sep 2016
Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to antibodies are treated differently to some other compounds in some jurisdictions. This article touches on some of the important requirements for antibody patenting in some major Asian jurisdictions, namely Japan, China and South Korea.